Trial Profile
Phase III study for evaluating efficacy and safety of a combination treatment of IDEC-C2B8 with steroid pulse therapy and plasmapheresis for antibody-mediated rejection after kidney transplant
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Steroids
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Zenyaku Kogyo
- 24 Oct 2018 New trial record